Restrictive cardiomyopathy
مراجعة من قبل الدكتورة توني هازيل، MRCGPآخر تحديث بواسطة الدكتور كولين تايدي، MRCGPLast updated 22 سبتمبر 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- Add to preferred sources on Google
المهنيين الطبيين
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our مقالاتنا الصحية more useful.
في هذه المقالة:
اعتلال عضلة القلب is defined as a 'myocardial disorder in which heart muscle is structurally and functionally abnormal without coronary artery disease, hypertension, valvular or congenital heart diseases'.1
There are five types, namely hypertrophic, dilated, arrhythmogenic, restrictive and unclassified. Cardiomyopathy is a significant cause of sudden cardiac death in young people.
تابع القراءة أدناه
What is restrictive cardiomyopathy?2
Restrictive cardiomyopathy is a heterogeneous group of diseases characterised by restrictive ventricular function with a rapid rise in ventricular pressure with only small increases in filling volume due to increased myocardial stiffness.
The defining feature is the coexistence of persistent restrictive pathophysiology, diastolic dysfunction, non-dilated ventricles, and atrial dilatation, regardless of ventricular wall thickness and systolic function.
Beyond this shared haemodynamic hallmark, the phenotypic spectrum of restrictive cardiomyopathy is wide. There are 4 main disease mechanisms:
Interstitial fibrosis and intrinsic myocardial dysfunction.
Infiltration of extracellular spaces.
Accumulation of storage material within cardiomyocytes.
Endomyocardial fibrosis.
There are separate articles which discuss Cardiomyopathies, Dilated Cardiomyopathies و Arrhythmogenic Right Ventricular Cardiomyopathy.
How common is restrictive cardiomyopathy? (Epidemiology)
العودة إلى المحتوياتRestrictive cardiomyopathy is the least common of the major cardiomyopathies, representing 2% to 5% of cases.3
However, restrictive cardiomyopathy is a leading cause of heart transplantation.
Familial inheritance is not characteristic of restrictive cardiomyopathy.
Restrictive cardiomyopathy is more prevalent in tropical Africa than in the Western world.
تابع القراءة أدناه
Causes of restrictive cardiomyopathy
العودة إلى المحتوياتOften no underlying cause is found. The causes of restrictive cardiomyopathies include:2
Familial:
Familial, unknown gene.
Sarcomeric protein mutations.
Troponin I (restrictive cardiomyopathy ± hypertrophic cardiomyopathy).
Essential light chain of myosin.
Familial الترانسثيريتيني.
Transthyretin (restrictive cardiomyopathy and neuropathy).
Apolipoprotein (restrictive cardiomyopathy and nephropathy).
Desminopathy.
Pseuxanthoma elasticum.
Anderson–Fabry disease.
Non-familial:
Amyloid (AL/prealbumin).
Endomyocardial fibrosis.
Hypereosinophilic syndrome.
Metastatic cancers.
Radiation.
Drugs (anthracyclines).
Idiopathic.
Infiltrative myocardial disease.
Cardiac الترانسثيريتيني - the most common cause of restrictive cardiomyopathy in the Western World.
The myocardium may be infiltrated by iron in haemochromatosis, glycogen in Pompe’s disease and Cori’s disease, or glycolipids in Fabry’s disease.
Restrictive cardiomyopathy symptoms (presentation)
العودة إلى المحتوياتUsually presents with heart failure but normal systolic function: dyspnoea, fatigue, loud third heart sound, pulmonary oedema, murmurs due to valve incompetence.
Heart size is usually normal or slightly enlarged.
Features of right ventricular failure predominate: raised JVP, with prominent x and y descents, hepatomegaly, oedema, ascites.
The clinical presentation of restrictive cardiomyopathy and constrictive pericarditis patients may be strikingly similar.4
Up to 75% of patients with idiopathic restrictive cardiomyopathy develop atrial fibrillation.5
تابع القراءة أدناه
التحقيقات2
العودة إلى المحتوياتRestrictive pathophysiology can be demonstrated by cardiac catheterisation or Doppler echocardiography.
The specific conditions may usually be diagnosed based on clinical data, 12-lead electrocardiogram, echocardiography, nuclear medicine, or cardiac MRI, but further investigations may be needed, such as endomyocardial biopsy and genetic evaluation.
التشخيص التفريقي
العودة إلى المحتوياتApart from constrictive التهاب التامور, which is the main differential diagnosis to consider, other constrictive diseases may mimic restrictive cardiomyopathy, so the following are often considered:
Metastases.
Radiation.
Cardiac tamponade - constrictive only.
Restrictive cardiomyopathy treatment and management2
العودة إلى المحتوياتDisease-modifying treatments are available only for cardiac amyloidosis and, partially, for iron overload cardiomyopathy.
In children, restrictive cardiomyopathy is primarily idiopathic, and transplantation is the treatment of choice.
Management of heart failure, including diuretics and angiotensin-converting enzyme (ACE) inhibitors. Loop diuretics to reduce pulmonary and peripheral oedema and ascites.
Amiodarone can reduce ventricular arrhythmias in high-risk patients.
All patients with restrictive cardiomyopathy and الرجفان الأذيني should be anticoagulated unless contra-indicated.5
Beta-blockers and non-dihydropyridine calcium-channel blockers may be used for rate control in those with atrial fibrillation.5 Beta-blockades may not be tolerated due to their negative chronotropic and, to a lesser extent, inotropic impact.
ت pacemaker may be required (patients are often not able to tolerate the cardiac dysfunction associated with arrhythmias).
Implantable cardioverter defibrillator: to prevent sudden death in high-risk patients.6
Heart transplantation may be indicated for some patients.
التكهن
العودة إلى المحتوياتVariable, depending on the underlying cause.
Restrictive cardiomyopathy due to amyloid has a worse prognosis.7
Cardiac amyloidosis is difficult to treat due to poor tolerance of most cardiovascular medication and poor outcome for transplantation.8
Recent advances in diagnosis and treatment of amyloid are, however, associated with improved prognosis.9
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.
قراءة إضافية ومراجع
- Ciarambino T, Menna G, Sansone G, et al; Cardiomyopathies: An Overview. Int J Mol Sci. 2021 Jul 19;22(14). pii: ijms22147722. doi: 10.3390/ijms22147722.
- Brown KN, Pendela VS, Ahmed I, et al; Restrictive Cardiomyopathy. StatPearls, Jan 2023.
- Vio R, Angelini A, Basso C, et al; Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies. J Clin Med. 2021 May 1;10(9):1954. doi: 10.3390/jcm10091954.
- Elliott P, Andersson B, Arbustini E, et al; Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. Epub 2007 Oct 4.
- Rapezzi C, Aimo A, Barison A, et al; Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022 Dec 1;43(45):4679-4693. doi: 10.1093/eurheartj/ehac543.
- Brieler J, Breeden MA, Tucker J; Cardiomyopathy: An Overview. Am Fam Physician. 2017 Nov 15;96(10):640-646.
- Zwas DR, Gotsman I, Admon D, et al; Advances in the differentiation of constrictive pericarditis and restrictive cardiomyopathy. Herz. 2012 Sep;37(6):664-73.
- Mohmand-Borkowski A, Tang WH; Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. Heart Fail Rev. 2014 May;19(3):295-304. doi: 10.1007/s10741-014-9424-0.
- Maron BJ; Can sudden cardiac death be prevented? Cardiovasc Pathol. 2010 Apr 7.
- Esplin BL, Gertz MA; Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013 Feb;38(2):53-96. doi: 10.1016/j.cpcardiol.2012.11.002.
- Sharma N, Howlett J; Current state of cardiac amyloidosis. Curr Opin Cardiol. 2013 Mar;28(2):242-8. doi: 10.1097/HCO.0b013e32835dd165.
- Chaulagain CP, Comenzo RL; New insights and modern treatment of AL amyloidosis. Curr Hematol Malig Rep. 2013 Dec;8(4):291-8. doi: 10.1007/s11899-013-0175-0.
تابع القراءة أدناه
About the authorView full bio

الدكتور كولين تايدي، MRCGP
General Practitioner, Medical Author
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy is an NHS Doctor, based in Oxfordshire.
About the reviewerView full bio

الدكتورة توني هازيل، MRCGP
MBBS, BSc, MRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
Dr. Toni Hazell qualified from St. Mary’s Hospital Medical School and did her VTS at Northwick Park Hospital.
تاريخ المقال
تمت كتابة المعلومات على هذه الصفحة ومراجعتها من قبل أطباء مؤهلين.
المراجعة التالية مستحقة: 20 سبتمبر 2028
22 سبتمبر 2023 | أحدث إصدار

اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.

هل تشعر بتوعك؟
قم بتقييم أعراضك عبر الإنترنت مجانًا